MedTrace Logo

Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD

NCT00263874 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 324

Last updated 2007-07-23

No results posted yet for this study

Summary

This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

UK-500,001

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Completion
2006-09-30

Countries

  • Argentina
  • Australia
  • Canada
  • Chile
  • Croatia
  • Czechia
  • Hungary
  • Singapore
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00263874 on ClinicalTrials.gov